Vector Purification Market

Vector Purification Market Overview

The vector purification market is estimated to be worth $155 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 21% during the forecast period. Since the approval and launch of cell and gene therapy products, such as Zolgensma® (2019), ZYNTEGLO™ (2019), Luxturna® (2017), KYMRIAH® (2017) and YESCARTA® (2017), there has been a significant increase in demand for viral vectors. Experts believe that the number of such therapies is likely to double over the next couple of years. It is also worth mentioning that this particular field of medical research received close to USD 10 billion in funding in 2019. Currently, over 1,000 cell and gene therapy-related clinical trials are being conducted, worldwide. Genetic manipulation is a basic requirement of cell and gene therapy development, and, as a result, gene delivery vectors are considered to be of utmost importance in viral vector purification market. So far, viral vectors (such as those based on adeno-associated viruses (AAV), adenoviruses, lentivirus, retroviruses and other viruses) have been shown to be the most versatile gene delivery tools available, having demonstrated high transfection efficiencies in both preclinical and clinical settings. Further, taking into account the therapeutic efficacy and low side effects profiles of cell and gene therapies, the demand for such interventions is anticipated to grow at a rapid pace, resulting in a proportional increase in need for appropriate vector systems, as well. However, viral vector development and manufacturing is a complex and cost intensive process. One of the primary concerns associated with viral vector production is related to yield; in fact, a singular batch run is estimated to incur losses of up to 70% during the purification step alone.  

A number of techniques are presently used for viral vector purification. Over the years, size-based viral purification strategies, such as density-gradient ultracentrifugation, ultrafiltration, precipitation and size-exclusion chromatography (SEC), have become part of the accepted industry standard. However, recently, stakeholders have begun relying more on affinity chromatography-based purification regimens, given its robustness and high selectivity. Presently, several companies claim to offer a diverse range of virus purification solutions, including, filter plates, prepacked chromatography columns and resins, and consolidated kits, for viral vector (virus) purification. As indicated earlier, downstream processing of viral vector products is challenging. Existing separation and purification techniques are not efficient when it comes to purifying viral vectors at large scales. Moreover, these techniques are often unable to separate complete viruses from empty capsids, thereby, compromising product recovery. Therefore, it has become essential for stakeholders to develop innovative ways to optimize the purification process, in order to further improve virus recovery and facilitate effective removal of contaminants / impurities. Currently, the viral vector purification products market is driven by abovementioned surge in demand for viral vectors. In this context, it is worth mentioning that there are several virus based vaccines under development against the novel SARS-CoV-2 coronavirus strain. In fact, according to the WHO, there are over 20 viral vaccines currently being investigated against the novel coronavirus. Developing the means to better purify viruses is, therefore, likely to significantly impact viable vaccine yield. The current crisis is definitely going to have a strong impact on the vector purification market and the market is likely to witness substantial market growth during the forecast period.

Key Companies in Vector Purification Market

Examples of key companies engaged in viral vector purification market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Agilent Technologies, BIA Separations, Bio-Rad Laboratories, BioVision, Cytiva (formerly GE Lifesciences), Merck, Sartorius, Takara Bio and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies providing virus / vector purification products, worldwide.

Recent Developments in Viral Vector Purification Market:

Several recent developments have taken place in the field of viral vector purification market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In July 2023, Biovian invested EUR 50 million to expand its manufacturing facility in Turku, Finland. Additionally, the new facility has an area of 6,400 sq m and will be used for manufacturing adenoviral and adeno-associated viral therapies. 
• In June 2023, Texcell announced the opening of a testing facility in North America with an aim to improve the viral safety of biotherapeutics and medical devices.

Scope of the Report

The ‘Vector Purification Market (kit, prepacked column, resin, cassette, filter plate, capsule, reagent and others), 2020-2030’ market report features an extensive study of various products available for vector purification market, in addition to the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the vector purification market. Amongst other elements, the market research report features: 

• An overview of the current market landscape of companies providing products for purification of viruses / viral vectors, using different techniques, such as chromatography, centrifugation and filtration. It features information on the type of product (kit, prepacked column, resin, cassette, filter plate, capsule and reagent), type of purification technique (chromatography, centrifugation and filtration),  scale of operation (lab-scale, clinical and commercial), type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others) and details on other physical and operational parameters of the product (such as matrix, pore size, volume of bed, flow rate, operating pressure, working temperature, pH, filtration area and process time). In addition, the chapter includes information on the purification product developers, including details on the year of establishment, company size and location of headquarters.
• Elaborate profiles of key players, including an overview of the company, product portfolio (viral vector purification products), recent developments and an informed future outlook.  
• An analysis evaluating the potential strategic partners (comprising of viral vector-based therapy developers and viral vector manufacturers) for viral vector purification product developers, based on several parameters, such as type of viral vector,  developer strength, operational strength, therapeutic area, strength of clinical pipeline and strength of preclinical pipeline.
• A clinical trial analysis of completed, ongoing and planned studies of various viral vector-based cell therapies, gene therapies and vaccines (approved / under development). It features detailed analyses of clinical studies of different viral-vector based therapies on the basis of their registration year, phase of development, trial status, type of therapy, therapeutic area, type of sponsor / collaborator, geographical location, number of patients enrolled and key players. 
• An informed estimate of the annual clinical and commercial demand (in terms of number of patients) for viral vectors, taking into account the marketed gene-based therapies and clinical studies evaluating vector-based therapies; the analysis also takes into consideration various relevant parameters, such as target patient population, dosing frequency and dose strength. Further, the demand has been segregated on the basis of type of viral vector, type of therapy, therapeutic are and geographical location. 
• A case study on tangential flow filtration (TFF), highlighting the role, advantages and disadvantages of the technique for purification of viral vectors; the chapter features details of products used for TFF, including product type, scale of operation, membrane material, flow rate and filtration area.
• A case study featuring the viral vector manufacturers providing commercial scale production, highlighting details on their year of establishment, company size, type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), purpose of production (in-house and contract-basis), and location of headquarters and manufacturing facilities. 

The key objective of viral vector purification market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for viral vector purification market during the forecast period. Based on various parameters, such as the likely increase in number of clinical studies related to viral vector-based therapies, anticipated growth in target patient population, existing price variations across different purification techniques, and the success of cell and gene therapy products (considering both approved and late-stage clinical candidates), we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the forecast period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] type of viral vector (AAV, adenovirus, lentivirus, retrovirus and others), [B] type of purification technique (chromatography, centrifugation and filtration), [C] type of therapy (gene therapy, cell therapy and viral vaccines) [D] therapeutic area (oncological disorders, cardiovascular disorders, ophthalmic disorders, metabolic disorders, inflammation & immunological diseases and others), [E] scale of operation (preclinical / clinical and commercial) and [F] key geographical regions (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this market report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the market research report were influenced by discussions held with several players in this industry. The market report includes detailed transcripts of discussions held with the following individuals: 

• Haifeng Chen (Chief Executive Officer, Virovek)
• Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
• Kai Lipinski (Chief Scientific Officer, Vibalogics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is virus purification?

Answer: Virus purification refers to the isolation viral vectors and facilitate effective removal of contaminants / impurities.

Question 2: How big is the vector purification market?

Answer: The vector purification market size is estimated to be worth $155 million in 2020.

Question 3: What is the projected market growth of the vector purification market?

Answer: The vector purification market is expected to grow at compounded annual growth rate (CAGR) of 21% during the forecast period 2020 – 2030.

Question 4: Who are the leading companies in the vector purification market?

Answer: Examples of key companies engaged in vector purification market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Agilent Technologies, BIA Separations, Bio-Rad Laboratories, BioVision, Cytiva (formerly GE Lifesciences), Merck, Sartorius, Takara Bio and Thermo Fisher Scientific.

Question 5: How many products are currently offered by companies engaged in the vector purification market?

Answer: Over 100 products are currently offered by players engaged in the vector purification market employing various viral vector isolating techniques.

Question 6: Which type of product is primarily offered by the companies engaged in vector purification market?

Answer: Primarily, majority (27%) of the players engaged in vector purification market offer purification kits.

Question 7: Which region is the hub for companies engaged in the vector purification market?

Answer: North America emerged as the hub for players engaged in the vector purification market, with over 60% of the companies established in the region.